

Committee to Evaluate Drugs (CED)

Recommendations and Reasons

Document Posted: May 2015

Linagliptin / Metformin

Product: linagliptin / metformin (Jentadueto®)

Class of Drugs: dipeptidyl peptidase-4 (DPP-4) inhibitor / biguanide

Reason for Use: type 2 diabetes

Manufacturer: Boehringer Ingelheim Canada Ltd.

Date of Review: October 9, 2013

CED Recommendation

The CED recommended that linagliptin/metformin (Jentadueto®) be funded, on the basis that this combination tablet may offer added patient convenience while providing cost savings to the program.

Executive Officer Decision*

Based on the CED's recommendation and an agreement with the manufacturer, the Executive Officer decided to fund linagliptin/metformin (Jentadueto®) on the Ontario Drug Benefit Formulary as a General Benefit with Therapeutic Notes.

Funding Status*

Funded on the Ontario Drug Benefit Formulary as a General Benefit with Therapeutic Notes.

** This information is current as of the posting date of the document. For the most up-to-date information on Executive Officer decision and funding status, see: www.health.gov.on.ca/en/pro/programs/drugs/status_single_source_subm.aspx*

Highlights of Recommendation:

- For this review, the CED considered:
 - Findings from the Common Drug Review and the recommendation of the Canadian Drug Expert Committee.
 - Information in the manufacturer's submission.
- Jentaducto® is a combination tablet containing two drugs, linagliptin and metformin, used for the treatment of type 2 diabetes. Both linagliptin and metformin as individual tablets are already funded on the Ontario Drug Benefit Formulary.
- Although there are no clinical studies evaluating the safety and efficacy of Jentaducto® specifically, several phase II and III studies have examined linagliptin and metformin used as combination therapy. The results of these studies demonstrated that linagliptin in combination with metformin provided superior or equivalent glycemic control relative to comparator treatments.
- There are several pharmacokinetic studies to show that Jentaducto® is equivalent to the combined administration of individual linagliptin and metformin tablets.
- At the submitted price, Jentaducto® costs \$2.37 per day. Economic analyses showed that the funding of Jentaducto® may result in cost savings to the program.
- Overall, studies have shown that combination therapy with linagliptin and metformin is effective in the treatment of type 2 diabetes. Jentaducto® is equivalent to individual components of linagliptin and metformin. This combination tablet may result in cost-savings.

Background:

Type 2 diabetes is a condition characterized by increased liver glucose output, reduced insulin secretion, and insulin resistance. Treatment involves oral anti-hyperglycemic agents and/or insulin when diet and exercise on their own do not result in better glycemic control.

Several anti-hyperglycemic drug classes are available in Canada to lower glucose levels. These include oral agents (e.g. biguanides, sulfonylureas, thiazolidinediones, meglitinides, alpha-glucosidase inhibitors, and incretin mimetics), insulins, and non-insulin injectables (i.e. glucagon-like peptide-1 (GLP-1) analogues).

Detailed Discussions:

There are no additional relevant details.

Committee to Evaluate Drugs (CED)

The Committee to Evaluate Drugs (CED) is comprised of practicing physicians, pharmacists, health economists, and patient representatives. In conducting its review, the CED considers data contained in the drug manufacturer's submission, input provided by patient groups, findings from the national Common Drug Review and the pan-Canadian Oncology Drug Review, and other scientific information as necessary.

For more information, please contact:

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Hepburn Block, 9th Floor

80 Grosvenor Street, Queen's Park

Toronto, Ontario M7A 1R3

www.health.gov.on.ca/en/pro/programs/drugs/